ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2144

JAK Inhibition Re-balances Gene Expression Profile of Circulating Immune Cells in Patients with Psoriatic Arthritis

Maria Gabriella Raimondo1, Charles Gwellem Anchang1, Hannah Labinsky2, Mina Saad Aziz Saad1, Simon Rauber1, Mario Vogg1, Eleni Kampylafka1, Johannes Knitza1, Alina Soare1, Georg Schett3 and Andreas Ramming1, 1Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054 Erlangen, Germany; Deutsches Zentrum Immuntherapie, Friedrich-Alexander-UniversityErlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, 2Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054 Erlangen, Germany; Deutsches Zentrum Immuntherapie, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, 3Universitätsklinikum Erlangen, Erlangen, Germany

Meeting: ACR Convergence 2022

Keywords: Disease-Modifying Antirheumatic Drugs (Dmards), Gene Expression, Monocytes/macrophages, Psoriatic arthritis, T Cell

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2022

Title: Spondyloarthritis Including PsA – Treatment Poster III: PsA

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: Janus Kinase (JAK)/Signal Transducers and Activator of Transcription (STAT) is not only involved in IL23- signaling, but rather implemented into a broad range of cytokine pathways. So far, most data on the molecular impact of JAK inhibition on immune cells were taken from isolated in vitro stimulation cells and. Specific changes in patients with PsA before and after treatment with JAK inhibitors in vivo have not been addressed. In a longitudinal study, we provide first data upon the effects of JAK inhibition upon circulating immune cells in a cohort of PsA patients.

Methods: 25 patients fulfilling the CASPAR classification criteria of PsA were included in the study. Peripheral blood mononuclear cells (PBMCs) were purified from 25 patients before and after an average of 16 weeks of treatment with tofacitinib (TOF). Clinical and laboratory parameters were collected, and disease activity score 28 (DAS28), disease activity in psoriatic arthritis (DAPSA), minimal disease activity score (MDA) were calculated. Immune cell profiling was performed on PBMCs before and after therapy by mass cytometry (CyTOF), addressing the major subtypes of IL17-producing cells (monocytes, T cells, natural killer cells and innate lymphoid cells). Single cell RNA-seq (scRNA-seq) was additionally performed before and after therapy to address the transcriptional profile of circulating immune cells.

Results: All patients had active PsA at the time of enrollment (DAS28 median 3.52, SD±0.8 and DAPSA median 20, SD±6.1). The DAPSA score dropped to remission level in 20% of patients, while 40%, 32% and 8% ended to have low, moderate and high disease activity, respectively. DAS28 showed similar distribution of responses. MDA was reached in 28% of the patients. CyTOF analysis did not show significant changes in cell frequency before and after treatment nor did it relate to DAPSA and DAS28 response. However, qualitative differences on transcriptional level were identified by scRNA-seq. Cell prioritization analysis showed CD4+naïve T cells and CD14+monocytes as the immune cells mostly affected by JAK inhibition. Differential gene expression showed an increase of downregulated genes with a downregulated/upregulated ratio of 1.4 in the CD4+naïve T cells, whereas monocytes had a ratio of 0.9.

Among the top dysregulated pathways in CD4+naïve T cells, we found a downregulation of genes involved in the Th17 differentiation as well as tumor necrosis factor (TNF), NFkB and JAK/STAT pathways. These changes in CD4+naïve T cells were associated with downregulation of apoptotic signaling and upregulation of metabolic pathways. Among them, oxidative phosphorylation was associated with the highest normalized enrichment score as compare to glycolysis.

Conclusion: JAK inhibition induced a different gene expression profile in circulating immune cells with prominent downregulation of pro-inflammatory pathways in CD4+naïve T cells as well as a shift in their metabolic signaling towards a more quiescent state.


Disclosures: M. Raimondo, None; C. Anchang, None; H. Labinsky, None; M. Saad, None; S. Rauber, None; M. Vogg, None; E. Kampylafka, None; J. Knitza, AbbVie, Novartis, ThermoFisher, UCB, ABATON, Sanofi, Medac, Lilly, BMS, Gilead, GSK, Werfen, Vila Health, Böhringer Ingelheim, Janssen, Galapagos, Chugai; A. Soare, None; G. Schett, None; A. Ramming, Boehringer-Ingelheim, Janssen, Gilead, Novartis, Pfizer.

To cite this abstract in AMA style:

Raimondo M, Anchang C, Labinsky H, Saad M, Rauber S, Vogg M, Kampylafka E, Knitza J, Soare A, Schett G, Ramming A. JAK Inhibition Re-balances Gene Expression Profile of Circulating Immune Cells in Patients with Psoriatic Arthritis [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/jak-inhibition-re-balances-gene-expression-profile-of-circulating-immune-cells-in-patients-with-psoriatic-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/jak-inhibition-re-balances-gene-expression-profile-of-circulating-immune-cells-in-patients-with-psoriatic-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology